The combination of red palm oil and rooibos show anti-inflammatory effects in rats by Katengua-Thamahane, Emma et al.
Katengua-Thamahane et al. Journal of Inflammation  (2014) 11:41 
DOI 10.1186/s12950-014-0041-4RESEARCH Open AccessThe combination of red palm oil and rooibos
show anti-inflammatory effects in rats
Emma Katengua-Thamahane1*, Jeanine L Marnewick2, Olawale R Ajuwon3, Novel N Chegou3, Gergő Szűcs4,
Péter Ferdinandy4,5, Tamás Csont4, Csaba Csonka4 and Jacques Van Rooyen1Abstract
Background: Red palm oil (RPO) and rooibos have been shown to exhibit cardioprotective properties. RPO is rich
in essential fatty acids and fat soluble antioxidants while rooibos contains polyphenolic compounds with a unique
composition of flavonoids. They exert their biological effects in different cellular compartments. Therefore the
combination of these two natural food compounds has the potential to enhance the spectrum of available dietary
antioxidants in different cellular compartments, which could result in an enhanced protection against certain
pathological conditions such as inflammation.
Methods: Male Wistar rats weighing 150-200 g were supplemented with RPO, rooibos or their combination for
28 days. The Langendorff system and the lipoposaccharide (LPS)-induced inflammatory model were used to establish
if RPO and rooibos, when supplemented alone or in combination, will reverse the negative effects of LPS on cardiac
function at baseline. The effect of dietary intervention was also investigated on modulation of pro-inflammatory and
anti-inflammatory cytokines in plasma and myocardial tissue.
Results and discussion: The LPS resulted in induction of systemic inflammation as evidenced by increased levels of
IL-1β in plasma of LPS-treated rats compared to their non-treated control counterparts. Dietary supplementation and
LPS treatment did not have an effect on baseline cardiac functional parameters. However, the elevation of IL-1β levels
in plasma of LPS-induced rats consuming either RPO or rooibos alone were paralleled with increased levels of the
anti-inflammatory cytokine, IL-10. The combination of rooibos and RPO was associated with enhanced endogenous
production of myocardial IL-10 in LPS-induced rats.
Conclusion: The results of this study indicate that RPO and rooibos when supplemented individually showed
anti-inflammatory effect at systemic level while their combination exhibited an enhanced anti-inflammatory effect
in the myocardial tissue. Therefore, the findings in the current study argue that the combination of these two natural
food substances could be beneficial in clinically relevant conditions where inflammation plays a role.Background
Natural food substances have the potential to alter bio-
logical functions of cellular and molecular components’
mechanisms by either enhancing the endogenous antioxi-
dant system or through altering the redox signalling status
of the cell [1]. This could be beneficial in pathological con-
ditions where oxidative stress and inflammation play an
important role. Previous studies have shown that rooibos
and red palm oil (RPO) protected the heart against the* Correspondence: ekatengua@yahoo.co.uk
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article, unless otherwise stated.detrimental effects of ischaemia/reperfusion injury when
supplemented individually to rats [2-7]. Experimental
evidence has also shown that RPO has potential anti-
hypertensive and hypoglycaemic properties [8]. Recent
evidence showed that RPO alone or in combination with
rooibos can alleviate oxidant-induced hepatotoxicity in
male rats [9].
Red palm oil is a product from the fruits of the oil palm
tree, Elaeis guineensis (Family Arecaceae) which has been
shown to have protective effects against hypercholesterol-
emia and atherosclerotic plaque formation, despite being
high in saturated fatty acids [10,11]. In addition to the
various fatty acids that RPO contains, it is also a rich
source of a wide spectrum of different lipid solubleioMed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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oids, lycopene and co-enzyme Q10, among others [12-14].
The health benefits of RPO have been attributed to its
unique composition of fatty acids and a high content of nat-
ural antioxidants [15,13]. RPO is one of the richest sources
of natural vitamin E, especially tocotrienols [16]. Vitamin E
has been shown to regulate specific cell signalling pathways
independent of its antioxidant properties, therefore some of
its beneficial effects have been attributed to its ability to
modulate signal transduction pathways [17,18]. There is
also credible evidence showing that palm oil vitamin E have
potential anti-inflammatory properties [19-22].
Rooibos is a uniquely South African herbal tea made
from the leaves and stems of the shrub-like leguminous
bush, Aspalathus linearis (Brum.f) Dahlg (Fabaceae, Tribe
Crotalarieae). It’s flavonoids are unique in that it contains
the C-C linked dihydrochalcone glucoside, aspalathin which
is oxidized to the flavanones dihydro-iso-orientin and
dihydro-orientin during fermentation, the cyclic dihydro-
chalcone, aspalalinin, the rare 3-dehydroxy dihydrochalcone
glucoside, nothofagin, the C-glycosyl flavones orientin,
isoorientin, vitexin, isovitexin, and the flavones hemiphlorin
and chrysoeriol, luteolin and luteolin-7-O-glucoside and
flavonols quercetin and its O-linked glycosides quercetin-3-
robinobioside, hyperoside, isoquercitrin and rutin [23-25].
The health effects of rooibos have been proposed to be
mostly attributed to the unique polyphenolic composition
and its related antioxidant activities [26-30]. Animal and
recent human studies have shown that consumption of
rooibos or its phenolic components had positive effects on
cardiovascular health and inflammation [31-38]. Studies
have shown that rooibos may have potential preventive and
therapeutic effects against vascular complications in dia-
betic rats [39]. Aspalathin, the main and unique polyphenol
in rooibos, has been shown to positively modulate glucose
homeostasis in type 2 diabetes [30], while the antioxidant
activity of rooibos has also been linked to its potential anti-
inflammatory and DNA protective effects in a rat colitis
model [33].
RPO (fat soluble) and rooibos (water soluble) contain
different types of antioxidants which reside and exert their
biological effects in different cellular compartments
[12,13,24,40]. Therefore, it is tempting to speculate that
supplementation with a combination of these two natural
food compounds can enhance the spectrum of available
dietary antioxidants in different cellular compartments
and hence offer a better protection against certain patho-
logical conditions such as inflammation. Accumulating
scientific evidence shows that inflammation is the under-
lying pathological cause for most chronic diseases, includ-
ing cardiovascular diseases, cancer and rheumatoid
arthritis [41-45]. Ischaemic heart disease is the common-
est form of cardiovascular disease leading to increased
morbidity and mortality [46]. The majority of heartattacks and strokes are caused by rupturing of the athero-
sclerotic plaque in the arterial wall and the tendency of
clot formation, which results from plaque rupture [46,42].
It is now a scientifically accepted fact that inflammation in
the lining of the artery is the triggering factor in the
pathogenesis of atherosclerosis [42]. It is becoming in-
creasingly evident that the use of non-toxic dietary supple-
ments either alone or in combination with pharmacological
agents could present an effective strategy in treatment and
prevention of the onset of acute and chronic inflammatory
diseases [47-50]. In this respect, Haines and co-workers
[47] reported that the combination of different phytonutri-
ents provided a more profound anti-inflammatory effect
than individual components acting independently. In an-
other study it has been shown that whole tart cherry extract
and specific anthrocyanins contained in the tart cherry ex-
hibited synergistic anti-inflammatory effects with lipitor in
reducing LPS-IL-6 induced secretion from adipose stem
cells [49]. Dietary intervention with a Jerte Valley
cherry-based beverage which is a rich source of antho-
cyanin pigments and other phenolic compounds has
been shown to modulate the balance between the levels
of pro and anti-inflammatory cytokines in young and
old ringdoves by down-regulating the levels of pro-
inflammatory cytokines and up-regulating the levels of
anti-inflammatory cytokines [48].
Administration of lipopolysaccharide (LPS) to animals is
widely used to study responses to in vivo-induced acute
systemic inflammation [51,52]. The inflammatory response
forms part of the host innate immune response, which rep-
resents the first line of defense against invading pathogens
or to injury [53]. The cytokine system forms an integral
part of the initial response to microbial agents. Cytokines
are also important pathophysiological mediators of cardio-
vascular pathologies such as atherosclerosis and systemic
sepsis-induced cardiac dysfunction [54,55]. The isolated rat
heart model and the LPS-induced inflammatory model
were used to determine if rooibos and RPO supplemen-
tation could protect against the negative effect of LPS-
induced inflammation on baseline cardiac function.Materials and methods
Animals received humane care in accordance with the
Principle of Laboratory Animal Care of the National Soci-
ety of Medical Research and the Guide for the care and use
of Laboratory animals of the National Academy of Sciences
(National Institutes of Health Publications no. 80–23,
revised 1978). The rats had free access to water or rooibos
and rat chow. They were individually caged in an experi-
mental animal facility at a constant room temperature of
27°C and exposed to a twelve-hour artificial day-night cycle.
The ethical clearance for this study was granted by the
Faculty of Health and Wellness Science’s Research Ethics
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Experimental model
Male Wistar rats weighing 150–200 g were randomly di-
vided into 8 groups and supplemented with fermented/
traditional rooibos, red palm oil (RPO) or their combination
for 28 days. The four groups were further subdivided into
two groups, either receiving 1) No-LPS or 2) LPS injection.
Group 1 which is the NO-LPS group consisted of the con-
trol group receiving standard rat chow and water, rooibos
group receiving standard rat chow and rooibos, RPO group
receiving standard rat chow supplemented with RPO 0.2
mL (7 g/kg diet) daily and water. The RPO concentrate was
supplied by Carotino SND BHD (Company no. 69046-T)
Malaysia. The composition of RPO consumed by the rats is
shown in (Table 1).
The rooibos + RPO group received a combination of
rooibos and RPO (without LPS treatment). Group 2 which
is the LPS group consisted of the control group receiving
standard rat chow and water, rooibos group receivingTable 1 Composition of Carotino RPO premium
consumed by the rats
Parameters Specifications Typical
Fatty acids% 0.1 max 0.058
Moisture and impurities,% 0.1 max 0.03
Iodine Value 48-53 51.2
Slip melting point, c 33-37 36.4
Carotenes, ppm 400 min 420
Tocopherols and Tocotrienols, ppm 400 min 860
Nutritional information
Amt/serving Qty per 14 g Qty per 100 g
Energy 518 kJ 3700 kJ
Protein 0.0 g 0.0 g
Fat, total 14 g 100 g
saturated 7.0 g 50.0 g
Trans 0.0 g 0.0 g
polyunsaturated 1.5 g 11.0 g
monounsaturated 5.5 g 39.0 g
Cholesterol 0.0 g 0.0 g
Carbohydrates 0.0 g 0.0 g
sugars 0.0 g 0.0 g
Sodium 0.0 g 0.0 mg
Carotenes as Vitamin A activity 640 ug 4600 ug
Vitamin E 2.5 mg 18.0 mg
Tocopherols 1.7 mg 12.0 mg
Tocotrienols 4.8 mg 34.0 mg
Certificate of analysis prescribed by Carotino 2010.
www.carotino.com.standard rat chow and rooibos, RPO group receiving
standard rat chow supplemented with RPO 0.2 mL
(equivalent to 7 g/kg diet) daily and rooibos + RPO group
receiving the combination of rooibos and RPO (with LPS
treatment). Superior grade fermented rooibos was provided
by Rooibos Ltd (Clanwilliam, South Africa). The rooibos
aqueous extract was prepared by the addition of 100 ml of
freshly boiled water to 10 g of tea leaves, filtered and stored
at −40°C, and diluted 5 times, a concentration customarily
used for tea consumption purposes, before being given to
the rats [56]. Phenolic content, antioxidant capacity and
flavonoids composition of the rooibos consumed by the
animals are as analyzed by Ajuwon et al. [9]. The animals
were given 100 ml of the freshly diluted rooibos every sec-
ond day. The rooibos and water consumption was moni-
tored throughout the feeding period and there were no
statistical differences observed in either rooibos or water
consumption among the experimental groups (data not
shown). At the end of the feeding period (28 days), 18 hours
prior to sacrificing, animals in the LPS group were injected
(intraperitoneal) with lipopolysaccharide (Escherichia coli
serotype) to induce inflammation. The LPS was dissolved
in sterile filtered phosphate buffered saline (PBS) to obtain
0.5 mg/kg body weight in 0.1 ml [51]. The animals in the
NO-LPS were injected (intraperitoneal) with 0.1 ml of PBS
(Table 2).
At the end of the feeding period and inflammation injec-
tion protocol, rats were fasted for 16 hours before sacrificed
and anaesthetized with an intraperitoneal injection of
2 mg/kg intraval sodium (sodium pentobarbital). Blood was
collected from the abdominal aorta (approximately 5–8 ml)
and placed into plain tubes for cytokine analysis. Serum
was then separated immediately by centrifuging at 5000 g
for 5 min at 4°C, the samples were then stored at −80°C till
analysis were performed. Hearts were rapidly excised and
placed in ice-cold Krebs-Henseleit buffer and transferred to
the Langendorff perfusion system. Hearts were perfused
with a Krebs-Henseleit buffer equilibrated with 95% O2 and
5% CO2 at 37°C (118.5 mM NaCl; 4.75 mM KCl; 1.2 mM
MgCl 6 H2O; 1.36 mM CaCl2; 25.0 mM NaHCO3; 1.2 mM
KH2PO4; 11.0 mM glucose) and a perfusion pressure
of 100cmH2O was maintained throughout the protocol.
Hearts were mounted to the Langendorff system and per-
fused for 15 minutes. Coronary flow, heart rate, LVDevP,
RPP, ±dp/dt max derivatives, EDLVP were documented at
baseline phase. LVDevP was measured with the aid of a bal-
loon made from transparent sandwich wrap film inserted
into the left ventricle through the opening of the left
atrium. The balloon was connected to a power lab system
(AD Instruments Pty Ltd., Castle Hill, Australia). After
insertion, the balloon was inflated to 2 mmHg, and the
contraction force of the heart against the balloon caused
water displacement that was converted to pressure. The
systolic and diastolic pressures as well as the heart rate and
Table 2 Study design illustrating the experimental groups and study protocol
NO-LPS LPS
Groups Control Rooibos RPO RB + RPO Control Rooibos RPO RB + RPO
Feeding time 28 days 28 days 28 days 28 days 28 days 28 days 28 days 28 days
Treatment PBS PBS PBS PBS LPS LPS LPS LPS
*Heart excision and perfusion protocol *Heart excision and perfusion protocol
RB: rooibos.
RPO: red palm oil.
LPS: liposaccharide.
Treatment: 0.5 mg/kg LPS was injected intraperitoneally to induce inflammation while 0.1 ml PBS was injected as a vehicle in control groups 18 hours prior to sacrificing.
*Hearts were excised and perfused for 20 minutes in a Langendorrf mode, baseline heart function was recorded at 20 minutes after which hearts were freeze
clamped for cytokine analysis.
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the computer. At the end of the perfusion protocol hearts
were removed from the system and stored at −80°C till
biochemical analysis were performed.
Immunoassay for plasma and myocardial cytokine analysis
Analyses of samples were performed on undiluted myo-
cardial tissue homogenates which were originally prepared
in phosphate buffer at a dilution of 1:4. In order to analyze
the myocardial cytokines, hearts from all the 8 groups
were freeze-clamped with Wollenberger clamp pre-cooled
in liquid nitrogen. The heart samples were then grinded
into powder and 100 mg of heart tissue powder was
diluted with 500 μl of phosphate buffer. The mixture was
homogenized by ultrasonic homogenizer at maximum
power (2×20 sec), and the homogenate was centrifuged at
4°C for 20 minutes at 5000 g. The supernatant was col-
lected and stored at −80°C till analyses were carried out.
Protein tissue content was determined using Bradford
technique [57]. Plasma and myocardial IL-1 beta, IL-6 and
IL-10 levels were measured using the Bio-Plex bead array
system (Bio Rad Laboratories, USA). Assays were carried
out in 96-well filter plates, while the rat cytokine kits,
(Cat#: RCYTO-80 K) were obtained from Millipore
(USA). Samples were evaluated in duplicate. All levels of
analytes in quality control reagents included in the kits
were within the expected references ranges.
Data analysis
Results were expressed as mean ± standard error of the
mean (SEM). Differences between the NO-LPS control
group and the LPS control group were determined using
an unpaired Student’s t-test. To compare differences in
multiple groups, ANOVA followed by FisherLSD post hoc
test was used. P < 0.05 was considered to be statistically
significant difference.
Results
Plasma cytokine levels
IL-1 β
The plasma pro-inflammatory cytokine IL-1β was signifi-
cantly increased (#p < 0.05) in LPS control (positivecontrols) rats (367.52 ± 60 pg/ml) when compared to the
NO-LPS control (negative controls) rats (63.71 ± 10 pg/ml)
(Figure 1a). No differences were observed in plasma.
IL-1β of the rooibos and RPO-supplemented LPS-
treated rats compared to the LPS control. No significant
differences were observed between RPO alone and the
combination treatment compared to the LPS control
(Figure 1a).
IL-6
The level of plasma pro-inflammatory cytokine, IL-6 in
the positive control rats was not significantly different
from the levels in the negative control animals. There
were also no differences observed in plasma IL-6 of LPS-
induced rooibos and RPO-supplemented rats compared to
the positive control (Figure 1b).
IL-10
The plasma anti-inflammatory cytokine, There were no
differences observed in plasma IL-10 levels between the
negative control and the positive control, however, a
significant increase (*p < 0.05) in plasma IL-10 level
observed in LPS-induced rats consuming rooibos
(4082.19 ± 180 pg/ml) compared to the positive control
(1462.63 ± 372 pg/ml). A similar pattern of results were
also observed for LPS-induced rats supplemented with
RPO, where the plasma IL-10 level was significantly
(*p < 0.05) increased (2375.28 ± 264 pg/ml) compared to
the positive control (1462.63 ± 372 pg/ml). There were
no differences observed in plasma IL-10 level of the
LPS-induced rats consuming the combination of rooibos
and RPO compared to the positive control (Figure 1c).
Myocardial cytokine levels
IL-1 β
When considering the myocardial IL-1β levels, there were
no differences observed between the NO-LPS control and
the LPS control animals. The level of myocardial IL-1β
was significantly (*p < 0.05) increased in LPS-induced
rats consuming the rooibos (172.36 ± 23 pg/ml) when
compared to the LPS control (73.29 ± 14 pg/ml) rats
(Figure 2a).
Figure 1 Effects of inflammation, rooibos and RPO on plasma IL-1β (a), IL-6 (b), and IL-10 (c) levels. Results are means ± SEM, n = 4-8/group.
#p < 0.05: LPS control vs NO-LPS control, *p < 0.05: treated vs. corresponding control. RPO: Red palm oil.
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Myocardial IL-6 was significantly (#p < 0.05) lower in the
positive control (121.53 ± 23 pg/ml) compared to the
negative control (233.85 ± 38 pg/ml) rats. The level of
myocardial IL-6 was significantly (*p < 0.05) increased in
LPS-treated rats consuming rooibos (235.58 ± 38 pg/ml)compared to the positive control (121.53 ± 23 pg/ml).
The LPS-induced rats which consumed the combin-
ation of rooibos and RPO also showed a significant
(*p < 0.05) increase in myocardial IL-6 (283.50 ± 29 pg/ml)
compared to the LPS control (121.53 ± 23 pg/ml),
(Figure 2b).
Figure 2 Effects of inflammation, rooibos and RPO on myocardial IL-1β (a), IL-6 (b), and IL-10 (c) levels. Results are means ± SEM, n = 5-7/group.
#p < 0.05: LPS control vs NO-LPS control, *p < 0.05: treated vs. corresponding control. RPO: Red palm oil.
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When considering the myocardial IL-10 levels, significantly
(#p < 0.05) increased levels of myocardial IL-10 weremeasured in the negative control (915.60 ± 71 pg/ml) com-
pared to the positive control (468 ± 60 pg/ml). While the
combination of rooibos and RPO significantly (*p < 0.05)
Katengua-Thamahane et al. Journal of Inflammation  (2014) 11:41 Page 7 of 12increased myocardial IL-10 levels (739.09 ± 48 pg/ml) com-
pared to positive control. The LPS-induced rats consuming
either rooibos or RPO alone did not show significant differ-
ences in induction of myocardial IL-10 compared to the
positive control (Figure 2c).
Discussion
The aim of the current study was to induce inflammation
in vivo and to establish if dietary supplementation with rooi-
bos and RPO would reverse or suppress the effects of inflam-
mation. We have shown that administration of LPS induced
systemic inflammation as evidenced by elevated levels of IL-
1β, the inflammation marker, in the plasma of LPS-treated
animals compared to non-treated animals. Consumption of
either rooibos or RPO alone was associated with elevated
levels of plasma anti-inflammatory cytokine (IL-10) in the
LPS-induced rats. The results indicate a potential anti-
inflammatory property of rooibos and RPO at systemic level
when supplemented individually. However, the combination
of rooibos and RPO significantly enhanced endogenous
myocardial IL-10 level in LPS-induced rats, arguing for
potential protection against inflammation on organ level.
Effects of inflammation, rooibos and RPO on IL-1β
The increased levels of plasma IL-1β in the LPS-induced
rats indicate that there was induction of inflammation in
response to the presence of the endotoxin (LPS), (Figure 1a).
IL-1β is one of the initial pro-inflammatory cytokines to be
released in response to the invading microbial pathogens
(specifically the lipopolysaccharide, an endotoxin embedded
within the bacterial membrane) and it plays a crucial role in
the induction of inflammation [58]. Therefore, increased
levels of circulating IL-1β are indicative of a systemic in-
flammatory response [59,60]. The response to LPS is initi-
ated upon the recognition of LPS by the LPS-binding
protein, following the binding of LPS to its binding protein
a series of multiple complex signalling pathways is initiated.
This will ultimately result in activation of the Toll-like Re-
ceptor (TLR) 4 through various adaptor proteins leading to
NF-κB activation and eventual induction of inflammatory
cytokines [61-64]. LPS triggers the release of inflammatory
cytokines from various cells of the immune system, the re-
leased cytokines leads to an acute inflammatory response
directed towards the invading pathogen [65-67]. The find-
ing of elevated plasma levels of IL-1β therefore confirms
that inflammation was induced in the current model. Our
results are in agreement with previous reports by Ohsaki
and co-workers [51] which used a similar dose of LPS and
showed increased IL-6 mRNA levels indicating that inflam-
mation was induced. Our results also show that supple-
mentation of either rooibos or red palm oil, together and
separate, could not prevent an increase in plasma IL-1β.
However, in the myocardium, our results show that
consumption of rooibos in the LPS-induced rats wasassociated with increased myocardial levels of IL-1β com-
pared to the positive control, while RPO and rooibos +
RPO did not affect the induction of myocardial IL-1β
(Figure 2a). Myocardial and endothelial cells have the cap-
acity to respond to LPS via activation of the TLRs leading
to induction of inflammatory cytokines [67]. The role of
cytokines in inflammation is complex and is determined by
various factors such as the magnitude of cytokine induction,
the presence of receptors to cytokines and also by the pres-
ence of antagonist mediators such as anti-inflammatory
cytokines. The increased levels of myocardial levels of IL-1β
in the LPS-induced rats consuming rooibos may represent
a normal cellular response to the presence of the endotoxin
[68], especially because the observed increases in myocar-
dial levels of IL-1β in LPS-induced rats consuming rooibos
were not associated with alterations cardiac function.
Effects of inflammation, rooibos and RPO on IL-6
Dietary intervention with rooibos, RPO or their combin-
ation did not have any effect on plasma IL-6 levels in
LPS-treated animals and their non-treated counterparts
(Figure 1b). There was differential modulation of myocar-
dial IL-6 by the dietary supplements in the LPS-induced
supplemented rats. Consumption of rooibos and that of
the combination of rooibos and RPO in LPS-induced rats
caused an increased in myocardial IL-6 compared to the
positive control level comparative to that of the negative
control animals (Figure 2b). Even though IL-6 is classic-
ally characterized as a pro-inflammation cytokine, it
has been shown to have both pro-inflammatory and
anti-inflammatory features [69,70]. IL-6 can evoke an
anti-inflammatory environment by inducing the pro-
duction of anti-inflammatory cytokines, such as IL-10
and IL-1ra in humans [70]. Our results show that the
increase in myocardial IL-6 in the LPS-induced rats
consuming rooibos and rooibos + RPO was associated
with enhanced up-regulation of myocardial IL-10.
Therefore the elevation of both IL-6 and IL-10 indicates
that in this instance, IL-6 might be acting as an anti-
inflammatory cytokine leading to enhancement of IL-10
production. There is evidence showing that in some
instances acute elevation of IL-6 may be beneficial, es-
pecially following exercise in humans [70]. Xing and
co-workers [71] showed that endogenous IL-6 plays an
anti-inflammatory role in both local and systemic acute
inflammatory responses in mice. This mechanism acts
by controlling the level of pro-inflammatory, but not
anti-inflammatory, cytokines [72]. Others have also
shown that blockade of IL-6 in patients with rheumatoid
arthritis led to enhanced cholesterol and plasma glucose
levels, indicating a role for IL-6 in modulation of glucose
and lipid metabolism [73,74]. Results in the current study
would therefore indicate that endogenous IL-6 rather pro-
tected than harmed the heart against induction of LPS,
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Figure 2b. The results further show that dietary interven-
tion can influence the levels of IL-6 in cardiac tissue. There
is also a difference between systemic and local response to
IL-6 levels with LPS induction in the presence of dietary
supplements such as red palm oil and rooibos. This needs
to be further investigated and clarified.
Effect of inflammation, rooibos and RPO on IL-10
The current results report that plasma IL-10 levels were
significantly elevated in the two LPS-treated groups con-
suming either rooibos or RPO when compared to the LPS
control. However, the LPS-induced rats consuming the
combination of rooibos and RPO did not show any effect
on plasma IL-10 levels indicating that there was no
additional benefit on plasma IL-10 levels when rooibos and
RPO were given in combination (Figure 1c). The results in-
dicate that dietary supplementation with rooibos and RPO
up-regulated the production of IL-10 in response to the
presence of inflammation. IL-10 is a potent anti-
inflammatory cytokine whose role is to counteract the ef-
fects of pro-inflammatory mediators in various forms of
shock and inflammation [75]. Inflammatory cells in the cir-
culation are activated in response to invasion of LPS and
the initial induction of inflammatory cytokines in response
to LPS is aimed at clearing local effect of the invading
pathogen [76]. However, the body has also evolved regula-
tory systems to maintain the balance between the levels of
pro-inflammatory mediators and anti-inflammatory media-
tors in order to sustain cellular homeostasis and immune
system integrity. We have shown that rooibos and RPO,
when supplemented individually, enhanced production of
IL-10 in the blood, suggesting a potential anti-inflammatory
effect at systemic level. Therefore the concomitant release
of IL-1 β and IL-10 in plasma of LPS-induced rats consum-
ing rooibos and RPO indicate that dietary intervention with
rooibos and RPO modulated the inflammatory response in
the model of inflammation by enhancing systemic produc-
tion of the anti-inflammatory cytokine. Rooibos is rich in
various polyphenolic compounds, some unique to the plant
as well, of which flavonoids are the most predominant [77].
Various polyphenolic molecules have been shown to exhibit
anti-inflammatory activity [78,79]. Polyphenols have a wide
range of biological effects which include antioxidant and
anti-inflammatory effects [80-83]. In the current study we
have shown that rooibos consumption was associated
with increased levels of plasma IL-10. This is in line
with previous studies where polyphenols were associ-
ated with enhanced production of IL-10 and suppres-
sion of IL-1β [81].
Just as polyphenols form a vital part of a healthy diet, vi-
tamins are also equally essential for human health. RPO is
rich in various forms of vitamin E and carotenoids which
function as cellular antioxidants [84,13]. Inflammationand oxidative stress are closely related and are usually
common features underlying etiological and pathological
mechanisms for most chronic diseases including cardio-
vascular diseases [85,86]. Both tocotrienols and tocopherol
are potent antioxidants and have also been shown to pos-
sess potential anti-inflammatory properties [19,22].
Dietary supplementation with the combination of rooibos
and RPO resulted in increased myocardial levels of IL-10 in
the LPS-induced rats compared to the positive control
while, when supplemented individually, rooibos and RPO
in the presence of LPS, did not have any effect on myocar-
dial IL-10 levels (Figure 2c), this result could be indicative
of a threshold needed to exert the effect, i.e. that of in-
creased IL-10 levels. To our knowledge this is the first evi-
dence showing that the combination of rooibos and RPO
resulted in up-regulation of myocardial IL-10 levels. Ele-
vated myocardial levels of IL-10 have been linked to cardio-
protection [87]. Endogenous production of IL-10 has been
shown to play an important role in maintaining myocardial
integrity during ischaemia-reperfusion via modulation of
the inflammation response. In this regard Yang et al. [88],
reported that genetic deletion of IL-10 was associated with
enhanced inflammation and increased myocardial infarc-
tion and necrosis.
Effects of inflammation, rooibos and RPO on baseline
cardiac functional parameters
LPS treatment and dietary supplementation with rooibos
and RPO did not have an effect on baseline cardiac func-
tional parameters. The increases in plasma IL 1β levels
and in myocardial tissue of the LPS-induced rooibos
group were not associated with ventricular dysfunction or
reduction in coronary flow (Table 3). This is contrary to
reports that IL-1β has a negative inotropic effect and that
it also leads to endothelial dysfunction [89,54]. The reason
for this could be that the dose of LPS that we used in this
study was sufficient to induce inflammation but not high
enough to induce cardiac dysfunction. In previous studies
where ventricular dysfunction was reported, higher doses
of LPS were used [90,91]. Lew et al. [92], also reported
that sub-lethal dose of LPS had minimal effect on cardiac
function. Another plausible reason could be that low
doses or sub-lethal doses of LPS have been shown to have
a pre-conditioning effect [93-95].
Conclusion
In this study we have shown that the model that we used
to induce inflammation has worked, as evidenced by in-
creased levels of IL-1β in the blood. Evidence presented
here, show for the first time, that the dietary combination
of rooibos and RPO significantly enhanced the up-
regulation of endogenous myocardial anti-inflammatory
IL-10 levels, a phenomenon shown to have great potential
in cardio-protection. This study also showed that IL-6 in
Table 3 Effects of inflammation, rooibos and RPO on baseline cardiac functional parameters in the NO-LPS group and the LPS group
LPS NO-LPS
Control Rooibos RPO RB + RPO Control Rooibos RPO RB + RPO
CF (ml/min) 13.92 ± 1.00 13.84 ± 1.00 14.6 ± 1.00 15.2 ± 1.00 14.30 ± 0.60 13.70 ± 0.70 14.60 ± 0.70 15.10 ± 0.20
HR bpm (1/min) 294.33 ± 6.00 277.87 ± 13.00 279.69 ± 15.00 296.313 ± 8.00 293.14 ± 14.00 302.39 ± 12.00 296.86 ± 10.00 300.00 ± 13.00
LVDevP (mmHg) 92.804 ± 6.00 86.40 ± 6.00 86.47 ± 5.00 97.00 ± 3.00 106.25 ± 4.30 89.60 ± 2.40 95.500 ± 4.50 100.90 ± 4.410
RPP (Bpm*mmHg) 27593.83 ± 1814.00 23706.98 ± 660.00 24383.99 ± 2503.00 28319.93 ± 764.00 30133.51 ± 1394.00 24805.68 ± 1366.00 24701.52 ± 1551.00 26176.72 ± 1212.00
dp/dt (+) (mmHg/sec) 2822.951 ± 149.00 2829.72 ± 84.00 2661.67 ± 198.00 2664.75 ± 112.00 3065.48 ± 103.00 2888.66 ± 129.00 2885.71 ± 80.00 2814.45 ± 113.00
dp/dt (−) (mmHg/sec) 1933.91 ± 70.00 1906.73 ± 82.00 1918.94 ± 103.00 1996.27 ± 94.00 2140.53 ± 90.00 1969.86 ± 69.00 2024.86 ± 120.00 1952.45 ± 51.00
EDLVP (mmHg) 10.256 ± 0.92 13.424 ± 2.20 11.558 ± 0.72 12.29 ± 1.34 13.74 ± 2.36 12.93 ± 1.33 12.22 ± 2.24 11.78 ± 1.16
HW (g) 1.17 ± 0.09 1.16 ± 0.05 1.11 ± 0.041 1.09 ± 0.03 1.32 ± 1.0 1.11 ± 0.0 2.82 ± 1.4 1.28 ± 0.1
BW (g) 333.70 ± 4.53 343.90 ± 10.02 346.60 ± 6.80 348.20 ± 3.40 350.20 ± 7.5 352.40 ± 7.4 334.20 ± 8.8 340.40 ± 90
No significant differences were observed in baseline cardiac function between the groups. Results are expressed as SEM, n = 5-7. CF- Coronary flow, HR- Heart rate, LVDevP- Left ventricular developed pressure,
RPP- Rate pressure product, dp/dt (+) - maximum of LVDevP derivative, dp/dt (-) - minimum of LVDevP derivative, EDLVP- End diastolic left ventricular pressure, HW- Heart weight,
BW- Body weight.
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than pro-inflammatory mediator. It was also evident from
the results that there is a difference in response to LPS in-
jection between the myocardium and the systemic circula-
tion. Therefore, the results argue that the combination of
these two natural food substances exhibit potential anti-
inflammatory properties worth investigating further.
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